The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 10, 2024
Filed:
Apr. 18, 2018
Applicant:
Fujifilm Cellular Dynamics, Inc., Madison, WI (US);
Inventors:
Maksym A. Vodyanyk, Madison, WI (US);
Xin Zhang, Madison, WI (US);
Andrew J. Brandl, Madison, WI (US);
Deepika Rajesh, Madison, WI (US);
Bradley Swanson, Madison, WI (US);
Christie Munn, Madison, WI (US);
Sarah Burton, Madison, WI (US);
Wen Bo Wang, Madison, WI (US);
Ethan McLEOD, Madison, WI (US);
Assignee:
FUJIFILM Cellular Dynamics, Inc., Madison, WI (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61K 35/545 (2015.01); C07K 14/725 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/17 (2013.01); A61K 35/545 (2013.01); C07K 14/7051 (2013.01); C12N 5/0646 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2501/01 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/145 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2311 (2013.01); C12N 2501/26 (2013.01); C12N 2501/727 (2013.01); C12N 2501/91 (2013.01); C12N 2506/11 (2013.01); C12N 2510/00 (2013.01);
Abstract
Provided herein are methods for the production of antigen-specific effector T cells and NK cells from pluripotent stem cells which express a chimeric antigen receptor (CAR). Further provided herein are methods for the adoptive cell therapy by administering the effector T cells and/or NK cells provided herein.